Breast cancer recurrence test ‘may reduce need for chemo’

A NEW breast cancer test which predicts the likelihood of cancer recurring could prevent thousands of women from undergoing unnecessary chemotherapy, its makers said.

The Oncotype DX test will benefit some of the 45,000 women diagnosed with breast cancer each year in Britain , according to molecular diagnostic company Genomic Health.

It creates “individualised tumour profiles” and provides personalised treatment decisions for patients and doctors, a spokesman for the company said.